Purified AAV Formulation for Stability and Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production and purification of adeno-associated virus (AAV) particles face challenges in maintaining viral infectivity and physical stability, with a propensity for aggregation, which affects the quality and consistency of gene therapy applications.
Innovation Solution
A pharmaceutical composition comprising purified AAV particles, a buffering agent, a cryoprotectant, and a non-ionic surfactant, with specific concentration ranges, is developed to enhance stability and reduce aggregation, including formulations with pharmaceutically acceptable salts like sodium chloride and poloxamer 188.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If AAV particles are purified to high purity, then product quality and safety are improved, but particle stability and infectivity may deteriorate
Solution Approach 1:
The patent introduces specific formulation components as intermediaries to protect purified AAV particles. These include buffering agents (Tris-HCl, HEPES) to maintain pH stability, cryoprotectants (sucrose, trehalose, glycerol) to prevent freezing damage, and non-ionic surfactants (poloxamer 188, polysorbate 80) to reduce aggregation. These intermediaries enable the particles to maintain both high purity and stability simultaneously
Solution Approach 2:
The patent optimizes formulation parameters including pH (7.0-8.0), ionic strength (50-200 mM NaCl), and additive concentrations to create conditions that preserve particle stability after purification. By carefully controlling these parameters, the formulation maintains particle integrity while allowing high purification levels
2Productivity
If AAV particles are stored after purification, then product availability is improved, but aggregation increases and stability decreases
Solution Approach 1:
The patent performs preliminary stabilization by adding protective agents before storage. The formulation includes cryoprotectants that prevent freezing damage during storage, and non-ionic surfactants that prevent aggregation before it occurs. This preliminary protection allows particles to be stored while maintaining stability
Solution Approach 2:
The formulation maintains continuous protection against aggregation and degradation through the presence of stabilizing agents. The buffering agents continuously maintain pH, cryoprotectants continuously prevent freezing damage, and surfactants continuously prevent particle aggregation, enabling long-term storage without loss of stability
3Reliability
If formulation components are added to maintain stability, then particle stability is improved, but formulation complexity increases
Solution Approach 1:
The patent uses multi-functional formulation components that perform multiple protective functions simultaneously. For example, sucrose serves as both a cryoprotectant and a stabilizing agent, while poloxamer 188 acts as both a surfactant and an anti-aggregation agent. This multi-functionality reduces the total number of components needed while maintaining comprehensive protection
Solution Approach 2:
The patent optimizes the concentrations of formulation components to achieve maximum stability with minimum complexity. By carefully tuning pH, ionic strength, and additive concentrations within specific ranges, the formulation achieves stable particle behavior without requiring excessive numbers of components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains or enhances AAV particle stability and reduces aggregation, ensuring high-quality products with consistent bioperformance even after multiple freeze/thaw cycles, as measured by dynamic light scattering and other assays.
Implementation Method 1
a buffering agent, wherein the buffering agent concentration is about 0 mM to about 50 mM
Implementation Method 2
a cryoprotectant, wherein the cryoprotectant is about 1% to about 10% (w/v)
Implementation Method 3
a non-ionic surfactant, wherein the non-ionic surfactant is about 0.0001% (w/v) to about 0.1% (w/v)
Data Source
AI summary
Formulations for highly purified viral particles (e.g., adeno-associated virus (AAV) particles) are provided herein. The formulations include purified AAV particles that are substantially free of impurities (e.g., product-related impurities and process-related impurities), and one or more of a buffering agent, a cryoprotectant, a non-ionic surfactant, and optionally a pharmaceutically acceptable salt. In certain aspects, the formulation maintains or enhances stability and/or reduces or prevents aggregation of the purified AAV particles.